Human Longevity, Inc. Signs Agreement with Genentech for Whole Genome Sequencing and Analysis of Samples Human Longevity, Inc. announced a multi-year agreement with Genentech, a member of the Roche Group, to conduct whole genome sequencing of tens of thousands of de-identified samples from Genentech. [Human Longevity, Inc.] Press Release Amgen and MD Anderson Announce Agreement to Develop BiTE® Therapies for Myelodysplastic Syndrome Amgen and The University of Texas MD Anderson Cancer Center announced a research collaborative agreement focusing on Amgen’s bispecific T cell engager (BiTE®) antibody constructs, an immunotherapy that serves as a “bridge” between T cells and cancer cells. [Amgen] Press Release Kymab Partners with Cancer Immunotherapy Expert on Anti-Cancer Therapeutics Kymab announced a collaboration with Dr. Stephen Gillies. Dr. Gillies is a pioneer in the field of cancer immunotherapy and inventor of immunocytokine platforms from which several molecules are currently in clinical development. [Kymab Limited] Press Release Treeway Announces License and Collaboration Agreement with uniQure to Develop a Gene Therapy for Amyotrophic Lateral Sclerosis (ALS) Treeway B.V. have announced a collaboration with uniQure N.V. to develop a gene therapy treatment for ALS. Under the terms of the licensing and collaboration agreement, uniQure has granted Treeway an exclusive license in this field to uniQure’s relevant AAV5 viral vector and glial cell-derived neurotrophic factor intellectual property. [Treeway B.V.] Press Release Boehringer Ingelheim and Yale University Collaborate to Investigate Novel Immunotherapy Targets Across Several Therapeutic Areas Boehringer Ingelheim announced a collaboration with Yale University with the goal of researching novel therapeutic targets in the field of immune-modulation. Under the terms of the agreement, the research capabilities of Boehringer Ingelheim and Yale University will be brought together to identify new immune-modulatory agents for oncology, autoimmune and respiratory disorders. [Boehringer Ingelheim GmbH] Press Release Intrexon, ZIOPHARM, and MD Anderson in Exclusive CAR T Pact Intrexon Corporation and its oncology partner, ZIOPHARM Oncology announced a broad exclusive licensing agreement with The University of Texas MD Anderson Cancer Center, including an exclusive sublicensing agreement through MD Anderson for intellectual property developed at the University of Minnesota for the development of non-viral adoptive cellular cancer immunotherapies. [Intrexon Corporation] Press Release Seattle Genetics and Bristol-Myers Squibb Announce Clinical Collaboration to Evaluate Combination of Adcetris® (Brentuximab Vedotin) and Opdivo® (Nivolumab) in Hematologic Malignancies Seattle Genetics, Inc. and Bristol-Myers Squibb Company announced that the companies have entered into a clinical trial collaboration agreement to evaluate the investigational combination of Seattle Genetics’ antibody-drug conjugate Adcetris and Bristol-Myers Squibb’s immunotherapy Opdivo in two planned Phase I/II clinical trials. [Bristol-Myers Squibb Company] Press Release Bristol-Myers Squibb and Lilly Enter Clinical Collaboration Agreement to Evaluate Opdivo (Nivolumab) in Combination with Galunisertib in Advanced Solid Tumors Bristol-Myers Squibb Company and Eli Lilly and Company announced a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of Bristol-Myers Squibb’s immunotherapy Opdivo in combination with Lilly’s galunisertib. [Bristol-Myers Squibb Company] Press Release Tekmira Pharmaceuticals and OnCore Biopharma Announce Merger Agreement to Create Leading Global Hepatitis B Virus Company Tekmira Pharmaceuticals Corporation and OnCore Biopharma, Inc. announced that they have agreed to merge to create a new leading global hepatitis B virus company focused on developing a curative regimen for hepatitis B patients by combining multiple therapeutic approaches. [Tekmira Pharmaceuticals Corporation] Press Release Bone Therapeutics Demonstrates Efficacy in First Patient Cohort in ALLOB® Phase I/IIa Delayed-Union Trial Bone Therapeutics announced positive efficacy results for the first cohort of four patients enrolled in the Phase I/IIa delayed-union trial with its allogeneic bone-forming cell product ALLOB®. [Bone Therapeutics] Press Release |